Showing 5681-5690 of 9946 results for "".
- Biosimilar News: Samsung Bioepis Secures US License Date for Proposed Stelara Biosimilarhttps://practicaldermatology.com/news/biosimilar-news-samsung-bioepis-secures-us-license-date-for-proposed-stelara-biosimilar/2462165/Samsung Bioepis Co., Ltd. signed a settlement and license agreement with Johnson & Johnson settling all pending US patent litigation between the two companies and clearing the way for commercialization of Samsung Bioepis’ SB17, a proposed biosimilar of reference medicine Stelara&nb
- Is Separating the Good Skin T Cells from the Bad Ones a Key to Treating Psoriasis and Vitiligo?https://practicaldermatology.com/news/is-separating-the-good-skin-t-cells-from-the-bad-ones-a-key-to-treating-psoriasis-and-vitiligo/2462162/New research highlights ways to remove immune cells that cause autoimmune skin diseases such as psoriasis and vitiligo without affecting protective cells that fight infection and cancer. Tissue-resident T cells or TRM cells fight infections and cancerous cells in the skin, but
- FDA Accepts Arcutis’ sNDA for Roflumilast Cream 0.15% for Treatment of AD in Adults and Children Down to Age 6https://practicaldermatology.com/news/fda-accepts-arcutis-snda-for-roflumilast-cream-015-for-treatment-of-ad-in-adults-and-children-down-to-age-6/2462159/The U.S. Food and Drug Administration (FDA) has accepted Arcutis’ supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6. Roflumilast cream is a once-daily, steroid
- Regenerative Medicine in Action: Reprogramming Tissue Mechanically to Heal Wounds, Rejuvenate Skinhttps://practicaldermatology.com/news/regenerative-medicine-in-action-reprogramming-tissue-mechanically-to-heal-wounds-rejuvenate-skin/2462156/Researchers have taken connective tissue cells that have been mechanically reprogrammed to resemble stem cells and transplanted them into damaged skin. In their laboratory experiment, they were able to show that the skin tissue model can actually be rejuvenated and that injur
- AD Pipeline Watch: Escient Pharmaceuticals Initiates Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonisthttps://practicaldermatology.com/news/ad-pipeline-watch-escient-pharmaceuticals-initiates-proof-of-concept-study-of-ep262-a-first-in-class-oral-mrgprx2-antagonist/2462155/The first subject has been dosed in EASE, a Phase 2a clinical proof-of-concept study of Escient Pharmaceuticals’ EP262 in atopic dermatitis (AD). By blocking activation of MRGPRX2 and degranulation of mast cells, EP262 has the potential to effectively treat multiple mast cell medi
- AD Pipeline Watch: Oral Zelnecirnon Shows Early Promise in ADhttps://practicaldermatology.com/news/ad-pipeline-watch-oral-zelnecirnon-shows-early-promise-in-ad/2462153/Zelnecirnon performed well in a Phase 1a/1b clinical trial of atopic dermatitis (AD), RAPT Therapeutics reports. Zelnecirnon is a small molecule oral therapy designed to selectively inhibit the migration of Th2 cells into inflamed tissues by blocking CCR4, a receptor highly express
- Beyond the Headlines: Dr. Jonathan Silverberg Reviews Maintenance Data on Rademikibart From a Pivotal Trial in Chinahttps://practicaldermatology.com/news/beyond-the-headlines-dr-jonathan-silverberg-reviews-maintenance-data-on-rademikibart-from-a-pivotal-trial-in-china/2462152/DermWire recently reported positive topline results from a 52-week maintenance study of rademikibart in people with atopic dermatitis (AD). At
- First Patients Enrolled in Phase 2 Proof of Concept Trial of MC2-25 VLS in Vulvar Lichen Sclerosushttps://practicaldermatology.com/news/first-patients-enrolled-in-phase-2-proof-of-concept-trial-of-mc2-25-vls-in-vulvar-lichen-sclerosus/2462151/The first patients have been enrolled in a Phase 2a proof of concept trial evaluating the safety and efficacy of MC2-25 VLS, a new drug candidate for the treatment of urea- associated skin diseases, including vulvar lichen sclerosus. MC2-25 VLS is a based on a di-peptide that
- Melanoma and Lung Cancer Drug May Also Treat Cutaneous Squamous Cell Carcinomahttps://practicaldermatology.com/news/melanoma-and-lung-cancer-drug-may-also-treat-cutaneous-squamous-cell-carcinoma/2462149/Plixorafenib, a new drug developed for treating melanoma and lung cancer, may also stop the progression of cutaneous squamous cell carcinoma, new research suggests. Researchers out of the University of Turku, Finland, discovered that plixorafenib (also called PLX8394) simultaneously inh
- DermaSensor Shows Promise for Skin Cancer Detectionhttps://practicaldermatology.com/news/dermasensor-shows-promise-for-skin-cancer-detection/2462147/DermaSensor, a handheld AI-powered spectroscopy device, works well at assessing skin lesions suggestive of skin cancer and should help primary care doctors improve their decision-making skills regarding appropriate referrals of skin cancer The new